Literature DB >> 15765789

Cytogenetic abnormalities without evidence of relapse after treatment with imatinib and stem cell transplantation in a patient with Ph-positive ALL.

Miwa Sakai, Kazuteru Ohashi, Takeshi Kobayashi, Takuya Yamashita, Hideki Akiyama, Hisashi Sakamaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15765789     DOI： 10.1532/ijh97.04179

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  14 in total

1.  Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

Authors:  M K Andersen; J Pedersen-Bjergaard; L Kjeldsen; I H Dufva; K Brøndum-Nielsen
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

2.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

Authors:  Thomas Bumm; Christel Müller; Haifa-Kathrin Al-Ali; Knut Krohn; Patricia Shepherd; Erika Schmidt; Sabine Leiblein; Christina Franke; Evelin Hennig; Thomas Friedrich; Reiner Krahl; Dietger Niederwieser; Michael W N Deininger
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

3.  Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation.

Authors:  K Offit; J P Burns; I Cunningham; S C Jhanwar; P Black; N A Kernan; R J O'Reilly; R S Chaganti
Journal:  Blood       Date:  1990-03-15       Impact factor: 22.113

4.  Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation.

Authors:  M Wakui; S Okamoto; A Ishida; R Tanosaki; T Mori; Y Kawai; S Ohshima; Y Ikeda
Journal:  Bone Marrow Transplant       Date:  1996-10       Impact factor: 5.483

5.  Hematopoietic recovery from host progenitors with normal karyotype devoid of Philadelphia chromosome in a patient with CML after allogeneic BMT.

Authors:  T Okamoto; A Kanamaru; H Wada; Y Takemoto; E Kakishita; T Hashimoto; J Furuyama; K Nagai
Journal:  Bone Marrow Transplant       Date:  1993-07       Impact factor: 5.483

6.  Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse.

Authors:  C G Brunstein; B A Hirsch; J S Miller; R C McGlennen; C M Verfaillie; P B McGlave; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2000-12       Impact factor: 5.483

7.  Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

Authors:  M E O'Dwyer; K M Gatter; M Loriaux; B J Druker; S B Olson; R E Magenis; H Lawce; M J Mauro; R T Maziarz; R M Braziel
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

8.  Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia.

Authors:  M F Bertheas; M Lafage; P Levy; D Blaise; A M Stoppa; P Viens; P Mannoni; D Maraninchi
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

9.  Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Authors:  Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Mary Beth Rios; Kimberly Hayes; Jorge Cortes
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

10.  The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.

Authors:  Eric Feldman; Vesna Najfeld; Michael Schuster; Gail Roboz; Amy Chadburn; Richard T Silver
Journal:  Exp Hematol       Date:  2003-08       Impact factor: 3.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.